Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 is now testing resistance at all-time highs, while
the Nasdaq is trading ~2% below that level. Distribution was unchanged this week at three and five days, respectively, with one expiring on each index on Wednesday. We will be looking for a breakout into new highs in
the coming days, however, to remain constructive on a potential pullback, we will be looking for the major averages to hold above their respective 21- and/or 50-DMA while avoiding any significant pickup in distribution. The
21-DMA is set to cross above the 50-DMA on both indices next week

Market View

The U.S. market has been moved back to a Confirmed Uptrend. The S&P 500 and Nasdaq are consolidating
gains after gapping above resistance at the 50-DMA. To remain constructive, we would like to see the 50-DMA
serve as support as more high quality ideas emerge from bases. Currently both indices are less than 2% off alltime highs with five distribution days on the Nasdaq and three on the S&P 500.

Market View

The U.S. market is in an Uptrend Under Pressure. The S&P 500 and Nasdaq are consolidating below their respective 50-DMA after advancing ~2.8% this week. Despite the move higher, we maintain a cautious outlook as
the 50-DMA has consistently been a level of resistance over the last four weeks. The distribution day count
stands at four days on the Nasdaq and three days on the S&P 500

Market View

The U.S. market is in an Uptrend Under Pressure. The S&P 500 and Nasdaq sold off more than 2.6% after trad-
ing slightly below resistance at the 50-DMA for several sessions. Each index picked up a distribution day, as the

count increased to three days on the Nasdaq and two on the S&P 500. Indices are poised to re-test August 5
lows, which is followed by support at the rising 200-DMA.

The selloff was broad-based as all 11 sectors declined, led lower by Energy (-3.3%), Transportation (-3.2%), Cy-
clical (-3.1%), and Technology (-3.1%). Nine of 11 sectors are trading below their 50-DMA including four—En-
ergy, Cyclical, Transportation, and Heath Care—below their 200-DMA. Of S&P 500 constituents, 67% are below

their 50-DMA and 48% are below their 200-DMA.

We maintain a cautious outlook as indices face upside resistance at their respective 50-DMA. Leadership re-
mains narrow and we advise reducing exposure as ideas break below long-term support levels. We believe a

defensive posture should be taken until the technical profile across indices, sectors, and groups improves.

Edwards Lifesciences

Key points:

The stock broke out of a cup-with-handle base on July 24 post print. It is constructively trading higher with support at its 21-DMA.
Fundamental ratings: EPS Rank 93, top Composite Rating 99, top SMR Rating A.
Technical ratings: RS line near all-time high, RS Rating 96, A/D Rating A

Market View

U.S. Market

The U.S. market is in an Uptrend Under Pressure. The S&P 500 and Nasdaq continue to whipsaw below 50-
DMA resistance. Though the Nasdaq did stage a day-six follow-through on Tuesday, gains were immediately
wiped out Wednesday with instant distribution. Further, few quality ideas have been set up technically to buy with
the majority chopping around within consolidation. Our primary expectation is that the August 5 lows (S&P 500:
2,822; Nasdaq: 7,662) are undercut and we eventually test the 200-DMA. This would result in the market status
being moved back to a Downtrend. We would change our current cautious outlook should indices rally strongly,
close, and importantly hold above their respective 50-DMA. Should that occur, we would move the market status
back to a Confirmed Uptrend.

Aug 15, 2019 – Key insight on recent IPOs

In this week’s webinar, Executive Director, Research Analyst Raj Gupta reveals the fundamental and technical characteristics our analysts believe are necessary for successful new issues. He will be joined by other O’Neil analysts, who will provide exclusive insight on recent IPOs and other ideas they are watching.

IPO Rewind

This report identifies a select group of IPOs or spin-offs that have priced in the last two years, giving them time to digest any initial volatility and release a few quarters of earnings. Our selected ideas display positive fundamental trends with strong top- and bottom-line consensus estimates, and IPO Rewind provides an efficient way to review these ideas that we believe warrant attention.

Market View

The U.S. market is in a Rally Attempt. The S&P 500 and Nasdaq have now held above Monday’s low for four

sessions. We are now looking for a follow-through day before shifting the market back into a Confirmed Up-
trend or, conversely, an undercut of Monday’s lows (S&P 500: 2,822; Nasdaq: 7,662) before shifting the market

back into a Downtrend. A follow-through day should feel like an explosive rally, with indices preferably up 1.7%

or more, on heavier volume than the day before. We would recommend a gradual increase in risk should a fol-
low-through day occur next week. Positively, both indices closed off their lows Friday after finding support at their

respective 100-DMA.
Following Monday’s selloff, multiple sectors, including Technology, rallied back strongly to narrowly recapture
their respective 50-DMA. Most, however, continue to chop around that level similar to the major averages. The
majority of leading ideas are doing the same—consolidating around their respective 50-DMA—though a select

few remain very strong, bucking general market weakness and continuing into new highs following better-than-
expected results. ~45% of S&P 500 and Nasdaq 100 stocks are trading above their respective 50-DMA.

Haemonetics Update

Key points:

  • The stock broke above a tight area of consolidation post print after finding strong support at its 50-DMA. We recommend holding core positions despite poor general market conditions given the Company’s very strong Q1 FY20 results and a long runway for future growth. Look to add to positions as the 21-DMA catches up to current prices.
  • Fundamental ratings: EPS Rank 83, Composite Rating 96, SMR Rating B.
  • Technical ratings: RS line at all-time highs, RS Rating 96, A/D Rating B+.